

FORM PTO-1449		Attorney Docket: 1004263.156US	Serial No.: 10/076,674
INFORMATION DISCLOSURE CITATION		Applicant: Kenneth Sokoll	
		Filing Date: February 14, 2002	Group Art Unit: 1648
U.S. PATENT DOCUMENTS			
Examiner Initial	Patent Number	Publication / Issue Date	Name

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, etc.)			
/NMM/	STERN, B. et al. "Vaccination with Tumor Peptide in CpG Adjuvant Protects Via IFN--Dependent CD4 Cell Immunity" <i>J. Immunology</i> (2002), 168:6099-6105		
/NMM/	MAURER, TA, et al. "CpG-DNA aided cross-presentation of soluble antigens by dendritic cells." <i>Eur. J. Immunol.</i> (2002), 32:2356-2364		
/NMM/	SINGH, M. et al. "Recent advances in vaccine adjuvants" <i>Pharmaceutical Research</i> , (2002), 19(6):715-728		
/NMM/	O'HAGEN, DT, et al. "Recent developments in adjuvants for vaccines against infectious diseases" <i>Biomolecular Engineering</i> (2001), 18:69-85		
/NMM/	SINGH, M, et al. "Recent advances in veterinary vaccine adjuvants" <i>International J. Parasitology</i> , (2003), 33:469-478		
/NMM/	O'HAGEN, DT, "Recent Developments in Vaccine Delivery Systems" <i>Current Drug Targets-Infectious Disorders</i> (2001), 1:273-286		
/NMM/	DITTMER, U, et al. "Treatment of infectious diseases with immunostimulatory oligodeoxynucleotides containing CpG motifs" <i>Current Opinion in Microbiology</i> , (2003), 6:472-477		
/NMM/	YOSHINAGA, T, et al. "DNA and its cationic lipid complexes induce CpG motif-dependent activation of murine dendrite cells" <i>Immunology</i> , (2006), 120:295-302		
/NMM/	RIEDL, P, et al. "Peptides containing antigenic and cationic domains have enhanced, multivalent immunogenicity when bound to DNA vaccines" <i>J. Mol. Med.</i> , (2004), 82:144-152		
/NMM/	DIMINSKY, D, et al. "Physical, chemical and immunological stability of CHO-derived hepatitis B surface antigen (HBsAg) particles" <i>Vaccine</i> , (2000), 18:3-17		
/NMM/	MORITA, T, et al. "Preparation of gelatin microparticles by co-lyophilization with poly(ethylene glycol): characterization and application to entrapment into biodegradable microspheres" <i>International J. Pharmaceutics</i> (2001), 219:127-137		
/NMM/	IVINS, B, et al. "Experimental anthrax vaccines: efficacy of adjuvants combined with protective antigen against an aerosol <i>Bacillus anthracis</i> spore challenge in guinea pigs" <i>Vaccines</i> , (1995), 13/18:1779-1784		
/NMM/	GUPTA, RK, et al. "Determination of protein loading in biodegradable polymer microspheres containing tetanus toxoid" <i>Vaccine</i> , (1997), 15(6/7):672-678		
/NMM/	HAKIM, I, et al. "A nine-amino acid peptide from IL-1beta augments antitumor immune responses induced by protein and DNA vaccines" <i>J. Immunol.</i> , (1996), 157:5503-5511		
/NMM/	ZENG, XY, et al. "Effects of active immunization against GnRH on serum LH, inhibin A, sexual development and growth rate in Chinese female pigs" <i>Theriogenology</i> (2002), 58:1315-1326		
/NMM/	PROIETTI, E, et al. "Type I IFN as a natural adjuvant for a protective immune response: lessons from the influenza Vaccine Model" <i>J. Immunol.</i> , (2002), 169:375-383		
/NMM/	"Foot and Mouth Disease" in OIE Manual of Standards for Diagnostic Tests and Vaccines, publisher: Springer Netherlands, Ch. 2.1.1, (1997)		
/NMM/	NESBURN, AB, et al. "Local and systemic B cell and Th1 responses induced following ocular mucosal delivery of multiple epitopes of herpes simplex virus type 1 glycoprotein D together with cytosine-phosphate-guanine adjuvant" <i>Vaccine</i> , (2005), 23:873-883		

Examiner	/N. M. Minnifield/ (08/29/2010)	Date Considered
EXAMINER:	Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	